Alfredo Perez Canabal, MD
Neurology · Mayaguez, PRNPI 1780789073
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by EMD Serono, Inc. at 33.1% of the total. Reporting peaked in 2019 at $1,296 and has fallen 76.3% since, to $307 in 2025.
Across 87 payments — averaging $49.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$1K
- Novartis$911
- Teva Pharmaceuticals USA, Inc.$293
- E.r. Squibb & Sons, L.L.C.$270
- Biogen$266
- AstraZeneca$217
- plus $946 from 12 others
What the payments were for
- Food & beverage$4,28299%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 18 | $1,436 |
| Novartis | 32 | $911 |
| Teva Pharmaceuticals USA, Inc. | 4 | $293 |
| E.r. Squibb & Sons, L.L.C. | 3 | $270 |
| Biogen | 4 | $266 |
| AstraZeneca | 2 | $217 |
| AbbVie(2 entities) | 2 | $155 |
| Sanofi | 1 | $125 |
| Eisai Inc. | 1 | $125 |
| Genentech USA, Inc. | 3 | $121 |
| Lilly USA, LLC | 3 | $100 |
| Mallinckrodt Enterprises LLC | 4 | $95 |
| Amgen | 1 | $91 |
| Eli Lilly Export S.A. Puerto Rico Branch | 4 | $52 |
| PBG Puerto Rico LLC | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Pfizer Pharmaceuticals LLC | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,338 in reported general payments places this provider in the 70th percentile of 129 neurology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AubagioTeriflunomide | 49 | $458,842 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 46 | $380,685 |
| Avonex (4 Pack)Interferon Beta-1a | 35 | $286,747 |
| CopaxoneGlatiramer Acetate | 45 | $258,755 |
| Plegridy PenPeginterferon Beta-1a | 29 | $238,288 |
| EnspryngSatralizumab-Mwge | 13 | $221,058 |
| Kesimpta PenOfatumumab | 22 | $210,048 |
| AustedoDeutetrabenazine | 11 | $157,849 |
| GilenyaFingolimod Hcl | 13 | $139,740 |
| TecfideraDimethyl Fumarate | 12 | $114,595 |
| VumerityDiroximel Fumarate | 12 | $104,749 |
| NuplazidPimavanserin Tartrate | 15 | $77,022 |
| UbrelvyUbrogepant | 50 | $74,684 |
| Rivastigmine | 481 | $54,017 |
| MestinonPyridostigmine Bromide | 22 | $50,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack), Tecfidera, Vumerity | $266 | $506,09159 claims |
| SanofiAubagio | $125 | $458,84249 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone, Austedo | $293 | $416,60556 claims |
| Genentech USA, Inc.Enspryng | $121 | $221,05813 claims |
| NovartisGilenya | $911 | $139,74013 claims |
| Acadia Pharmaceuticals IncNuplazid | $15 | $77,02215 claims |
| AbbVieUbrelvy | $155 | $74,68450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Mayaguez
- Luis NataliMayaguez$5K
- Jose AcevedoMayaguez$4K
- Merbil Gonzalez DiazMayaguez$3K
- Angel ChineaGuaynabo$1.7M
- Jose Avila OrnelasCaguas$538K
- Franchesca Fiorito-TorresSan Juan$453K
- Patricia de JesusCaguas$310K
- Mari GarciaSan Juan$138K
- Cristina Cabret-AymatSan Juan$108K
- Gishlaine Alfonso MendezSan Juan$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.